Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin

Z. M. Younossi, M. Stepanova, Kathleen Schwarz, S. Wirth, P. Rosenthal, R. Gonzalez-Peralta, K. Murray, L. Henry, S. Hunt

Research output: Contribution to journalArticle

Abstract

Chronic HCV infection has been associated with impairment of HRQL in both adults and paediatric patients. Our aim was to assess the HRQL of HCV-positive children treated with SOF + RBV. The data for this post hoc analysis were collected in a phase 2 open-label multinational study that evaluated safety and efficacy of SOF (400 mg/day) plus RBV (weight-based up to 1400 mg/day) for 12 or 24 weeks in adolescents with chronic HCV (GS-US-334-1112). Patients and their parents/guardians completed the PedsQL-4.0-SF-15 questionnaire at baseline, at the end of treatment and in post-treatment follow-up. We included 50 adolescents with HCV genotype 2 and 3 without cirrhosis (14.8 ± 1.9 years; male: 58%; treatment-naïve: 82%; vertically transmitted HCV: 70%). After treatment, 100% of patients with HCV genotype 2 and 95% with genotype 3 achieved SVR-12. During treatment with SOF + RBV, there were no significant decrements in any of patients’ self-reported or parent-proxy-reported PRO scores regardless of treatment duration (all P >.05). After treatment cessation, we recorded a statistically significant improvement in patients’ self-reported Social Functioning score by post-treatment week 12: on average, +4.8 points on a 0-100 scale (P =.02). By post-treatment week 24, parent-proxy-reported School Functioning score increased by, on average, +13.0 points (P =.0065). In multivariate analysis, history of abdominal pain and psychiatric disorders were predictive of impaired HRQL in adolescents with HCV (P <.05). Adolescents with HCV do not seem to experience any HRQL decrement during treatment with SOF + RBV and experience some improvement of their HRQL scores after achieving SVR.

Original languageEnglish (US)
Pages (from-to)354-362
Number of pages9
JournalJournal of Viral Hepatitis
Volume25
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Ribavirin
Hepatitis C
Quality of Life
Therapeutics
Genotype
Proxy
Sofosbuvir
Somatoform Disorders
Withholding Treatment
Abdominal Pain
Psychiatry
Fibrosis
Multivariate Analysis
Parents
Pediatrics
Safety
Weights and Measures

Keywords

  • direct-acting antiviral
  • emotional well-being
  • paediatric
  • physical well-being
  • social functioning

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

Younossi, Z. M., Stepanova, M., Schwarz, K., Wirth, S., Rosenthal, P., Gonzalez-Peralta, R., ... Hunt, S. (2018). Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. Journal of Viral Hepatitis, 25(4), 354-362. https://doi.org/10.1111/jvh.12830

Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. / Younossi, Z. M.; Stepanova, M.; Schwarz, Kathleen; Wirth, S.; Rosenthal, P.; Gonzalez-Peralta, R.; Murray, K.; Henry, L.; Hunt, S.

In: Journal of Viral Hepatitis, Vol. 25, No. 4, 01.04.2018, p. 354-362.

Research output: Contribution to journalArticle

Younossi, ZM, Stepanova, M, Schwarz, K, Wirth, S, Rosenthal, P, Gonzalez-Peralta, R, Murray, K, Henry, L & Hunt, S 2018, 'Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin', Journal of Viral Hepatitis, vol. 25, no. 4, pp. 354-362. https://doi.org/10.1111/jvh.12830
Younossi ZM, Stepanova M, Schwarz K, Wirth S, Rosenthal P, Gonzalez-Peralta R et al. Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. Journal of Viral Hepatitis. 2018 Apr 1;25(4):354-362. https://doi.org/10.1111/jvh.12830
Younossi, Z. M. ; Stepanova, M. ; Schwarz, Kathleen ; Wirth, S. ; Rosenthal, P. ; Gonzalez-Peralta, R. ; Murray, K. ; Henry, L. ; Hunt, S. / Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. In: Journal of Viral Hepatitis. 2018 ; Vol. 25, No. 4. pp. 354-362.
@article{95399b4d1a9c428ba7d1aad3230d8c05,
title = "Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin",
abstract = "Chronic HCV infection has been associated with impairment of HRQL in both adults and paediatric patients. Our aim was to assess the HRQL of HCV-positive children treated with SOF + RBV. The data for this post hoc analysis were collected in a phase 2 open-label multinational study that evaluated safety and efficacy of SOF (400 mg/day) plus RBV (weight-based up to 1400 mg/day) for 12 or 24 weeks in adolescents with chronic HCV (GS-US-334-1112). Patients and their parents/guardians completed the PedsQL-4.0-SF-15 questionnaire at baseline, at the end of treatment and in post-treatment follow-up. We included 50 adolescents with HCV genotype 2 and 3 without cirrhosis (14.8 ± 1.9 years; male: 58{\%}; treatment-na{\"i}ve: 82{\%}; vertically transmitted HCV: 70{\%}). After treatment, 100{\%} of patients with HCV genotype 2 and 95{\%} with genotype 3 achieved SVR-12. During treatment with SOF + RBV, there were no significant decrements in any of patients’ self-reported or parent-proxy-reported PRO scores regardless of treatment duration (all P >.05). After treatment cessation, we recorded a statistically significant improvement in patients’ self-reported Social Functioning score by post-treatment week 12: on average, +4.8 points on a 0-100 scale (P =.02). By post-treatment week 24, parent-proxy-reported School Functioning score increased by, on average, +13.0 points (P =.0065). In multivariate analysis, history of abdominal pain and psychiatric disorders were predictive of impaired HRQL in adolescents with HCV (P <.05). Adolescents with HCV do not seem to experience any HRQL decrement during treatment with SOF + RBV and experience some improvement of their HRQL scores after achieving SVR.",
keywords = "direct-acting antiviral, emotional well-being, paediatric, physical well-being, social functioning",
author = "Younossi, {Z. M.} and M. Stepanova and Kathleen Schwarz and S. Wirth and P. Rosenthal and R. Gonzalez-Peralta and K. Murray and L. Henry and S. Hunt",
year = "2018",
month = "4",
day = "1",
doi = "10.1111/jvh.12830",
language = "English (US)",
volume = "25",
pages = "354--362",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin

AU - Younossi, Z. M.

AU - Stepanova, M.

AU - Schwarz, Kathleen

AU - Wirth, S.

AU - Rosenthal, P.

AU - Gonzalez-Peralta, R.

AU - Murray, K.

AU - Henry, L.

AU - Hunt, S.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Chronic HCV infection has been associated with impairment of HRQL in both adults and paediatric patients. Our aim was to assess the HRQL of HCV-positive children treated with SOF + RBV. The data for this post hoc analysis were collected in a phase 2 open-label multinational study that evaluated safety and efficacy of SOF (400 mg/day) plus RBV (weight-based up to 1400 mg/day) for 12 or 24 weeks in adolescents with chronic HCV (GS-US-334-1112). Patients and their parents/guardians completed the PedsQL-4.0-SF-15 questionnaire at baseline, at the end of treatment and in post-treatment follow-up. We included 50 adolescents with HCV genotype 2 and 3 without cirrhosis (14.8 ± 1.9 years; male: 58%; treatment-naïve: 82%; vertically transmitted HCV: 70%). After treatment, 100% of patients with HCV genotype 2 and 95% with genotype 3 achieved SVR-12. During treatment with SOF + RBV, there were no significant decrements in any of patients’ self-reported or parent-proxy-reported PRO scores regardless of treatment duration (all P >.05). After treatment cessation, we recorded a statistically significant improvement in patients’ self-reported Social Functioning score by post-treatment week 12: on average, +4.8 points on a 0-100 scale (P =.02). By post-treatment week 24, parent-proxy-reported School Functioning score increased by, on average, +13.0 points (P =.0065). In multivariate analysis, history of abdominal pain and psychiatric disorders were predictive of impaired HRQL in adolescents with HCV (P <.05). Adolescents with HCV do not seem to experience any HRQL decrement during treatment with SOF + RBV and experience some improvement of their HRQL scores after achieving SVR.

AB - Chronic HCV infection has been associated with impairment of HRQL in both adults and paediatric patients. Our aim was to assess the HRQL of HCV-positive children treated with SOF + RBV. The data for this post hoc analysis were collected in a phase 2 open-label multinational study that evaluated safety and efficacy of SOF (400 mg/day) plus RBV (weight-based up to 1400 mg/day) for 12 or 24 weeks in adolescents with chronic HCV (GS-US-334-1112). Patients and their parents/guardians completed the PedsQL-4.0-SF-15 questionnaire at baseline, at the end of treatment and in post-treatment follow-up. We included 50 adolescents with HCV genotype 2 and 3 without cirrhosis (14.8 ± 1.9 years; male: 58%; treatment-naïve: 82%; vertically transmitted HCV: 70%). After treatment, 100% of patients with HCV genotype 2 and 95% with genotype 3 achieved SVR-12. During treatment with SOF + RBV, there were no significant decrements in any of patients’ self-reported or parent-proxy-reported PRO scores regardless of treatment duration (all P >.05). After treatment cessation, we recorded a statistically significant improvement in patients’ self-reported Social Functioning score by post-treatment week 12: on average, +4.8 points on a 0-100 scale (P =.02). By post-treatment week 24, parent-proxy-reported School Functioning score increased by, on average, +13.0 points (P =.0065). In multivariate analysis, history of abdominal pain and psychiatric disorders were predictive of impaired HRQL in adolescents with HCV (P <.05). Adolescents with HCV do not seem to experience any HRQL decrement during treatment with SOF + RBV and experience some improvement of their HRQL scores after achieving SVR.

KW - direct-acting antiviral

KW - emotional well-being

KW - paediatric

KW - physical well-being

KW - social functioning

UR - http://www.scopus.com/inward/record.url?scp=85039156031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039156031&partnerID=8YFLogxK

U2 - 10.1111/jvh.12830

DO - 10.1111/jvh.12830

M3 - Article

VL - 25

SP - 354

EP - 362

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 4

ER -